5-HT3 RECEPTOR ANTAGONISTS INHIBIT MORPHINE-INDUCED STIMULATION OF MESOLIMBIC DOPAMINE RELEASE AND FUNCTION IN THE RAT

被引:72
作者
PEI, Q [1 ]
ZETTERSTROM, T [1 ]
LESLIE, RA [1 ]
GRAHAMESMITH, DG [1 ]
机构
[1] UNIV OXFORD, RADCLIFFE INFIRM, SMITHKLINE BEECHAM CTR APPL NEUROPSYCHOBIOL, OXFORD OX2 6HE, ENGLAND
关键词
MORPHINE; MESOLIMBIC DOPAMINE; 5-HT3 RECEPTOR ANTAGONISTS; MICRODIALYSIS;
D O I
10.1016/0014-2999(93)90410-J
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of three different 5HT3 receptor antagonists, granisetron, ICS 205-930 and ondansetron (0.01, 0.1 and 1 mg/kg, s.c.) were tested on changes in mesolimbic dopamine function produced by 1 mg/kg of morphine in the rat. Increases of in vivo dopamine release and stimulation of behavioural activity (grooming, locomotion, rearing and sniffing) were monitored. Morphine (0.5 and 1 mg/kg, s.c.) increased dose-dependently the concentration of dopamine in dialysates obtained from the nucleus accumbens. This action of morphine was inhibited by the opiate antagonist naloxone (1 mg/kg, s.c.). Morphine (0.5 and 1 mg/kg) stimulated behavioural activity, which in the early part of the time course corresponded closely with the increase of dopamine in the nucleus accumbens. Pretreatment with 1 mg/kg (s.c.) of granisetron resulted in moderate inhibition (28%) of the morphine-induced stimulation of the extracellular dopamine levels, while doses of 0.01 and 0.1 mg/kg (s.c.) had no effect. The highest dose of granisetron (i mg/kg, s.c.) also significantly reduced the morphine-induced enhancement of behavioural activity. The fact that granisetron attenuated morphine-induced effects on mesolimbic DA only at the highest dose tested (1 mg/kg, s.c.) was also true for ICS 205-930 and ondansetron. It is concluded that 5HT3 receptor antagonists partially inhibit, with low potency, the morphine-induced stimulation of dopamine release in the nucleus accumbens and the corresponding behavioural activation.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 38 条
[1]   CHARACTERIZATION AND AUTORADIOGRAPHIC LOCALIZATION OF 5-HT3 RECEPTOR RECOGNITION SITES IDENTIFIED WITH [3H]-(S)-ZACOPRIDE IN THE FOREBRAIN OF THE RAT [J].
BARNES, JM ;
BARNES, NM ;
CHAMPANERIA, S ;
COSTALL, B ;
NAYLOR, RJ .
NEUROPHARMACOLOGY, 1990, 29 (11) :1037-&
[2]   5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTAMINERGIC-DOPAMINERGIC INTERACTIONS IN THE VENTRAL TEGMENTAL AREA OF RAT-BRAIN [J].
BEART, PM ;
MCDONALD, D .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1982, 34 (09) :591-593
[3]  
BLANDINA P, 1989, J PHARMACOL EXP THER, V251, P803
[4]   5-HT3 RECEPTOR ANTAGONISTS BLOCK MORPHINE-INDUCED AND NICOTINE-INDUCED PLACE-PREFERENCE CONDITIONING [J].
CARBONI, E ;
ACQUAS, E ;
LEONE, P ;
PEREZZANI, L ;
DICHIARA, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 151 (01) :159-160
[5]   DIFFERENTIAL INHIBITORY EFFECTS OF A 5-HT3 ANTAGONIST ON DRUG-INDUCED STIMULATION OF DOPAMINE RELEASE [J].
CARBONI, E ;
ACQUAS, E ;
FRAU, R ;
DICHIARA, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 164 (03) :515-519
[6]   ACTIVATION OF 5-HT3 RECEPTOR BY 1-PHENYLBIGUANIDE INCREASES DOPAMINE RELEASE IN THE RAT NUCLEUS-ACCUMBENS [J].
CHEN, J ;
VANPRAAG, HM ;
GARDNER, EL .
BRAIN RESEARCH, 1991, 543 (02) :354-357
[7]   THE PSYCHOPHARMACOLOGY OF 5-HT3 RECEPTORS [J].
COSTALL, B ;
NAYLOR, RJ ;
TYERS, MB .
PHARMACOLOGY & THERAPEUTICS, 1990, 47 (02) :181-202
[8]  
Costall B, 1990, Neuroreport, V1, P77, DOI 10.1097/00001756-199009000-00021
[9]  
DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
[10]  
DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067